Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Feasibility Study in Chronically Fatigued Cancer Survivors

20 de abril de 2022 atualizado por: Lene Thorsen, Oslo University Hospital

Improved cancer survival has led to increased attention on long-term health and quality of life (QoL) among the survivors. Both the cancer diagnosis and intensive treatments increase the risk of late effects which may interfere with daily physical, psychological and social functioning, and thereby negatively affect their QoL. Well-documented late-effects among cancer survivors are second cancer, cardio-vascular disease, pain, hormone disturbances, mental distress and chronic fatigue (CF).

CF is a subjective experience of substantial lack of energy, exhaustion and cognitive difficulties lasting for six months or longer. CF is one of the most common and distressing late effects after cancer, affecting 15-35 % of survivors, often for years beyond treatment. Despite the high prevalence and the huge negative consequences of CF on daily functioning and QoL and the economic and societal costs, effective treatment of CF and standardized follow-up care are currently lacking.

CF is a complex condition best understood as a multifactorial phenomenon. Our and other research groups have examined various cohorts of cancer survivors in order to identify behavioral-, psychological-, and biological factors associated with CF, that can form the basis for targeted interventions. So far, few treatable biological factors have been identified, even though immune activation, flattened diurnal cortisol slopes and a blunted cortisol response to stress have been demonstrated in small studies among cancer survivors suffering from CF. On the other hand, several modifiable behavioral factors including emotional distress, physical inactivity, sleep disturbances and unhealthy diets are found to be associated with CF. So far, most of the interventions aiming to reduce fatigue during and shortly after cancer treatment have targeted only one of these factors at a time, with small to moderate effect sizes. No prior study has examined if CF in cancer survivors is better treated by a complex intervention targeting combinations of these factors, an approach which seems logical due to the complexity of the symptom.

The Division of Cancer Medicine at Oslo University Hospital (OUH) presently offers limited rehabilitation programs, including patient education, physical exercise, cognitive behavioral program and nutrition counselling to cancer survivors with CF. However, these programs are not offered as an interdisciplinary intervention integrated in a standardized patient care pathway, and the effects of these interventions have not been assessed. Based on the investigators clinical experience and published studies on single-targeted interventions, the investigators hypothesize that a complex intervention including psycho-educational elements, physical exercise and nutrition counseling delivered as a standardized patient care pathway is well-founded and doable, and will improve fatigue, functioning and QoL in cancer survivors with CF.

During the fall of 2021, the investigators will conduct a randomized controlled trial (RCT) with the overall objective to improve fatigue in lymphoma survivors with CF. To uncover strengths and weaknesses with the planned RCT, i.e. the inclusion procedures, the assessments and the complex intervention, the investigators are now conducting a small one-armed feasibility study before the RCT during spring 2021.

Visão geral do estudo

Status

Concluído

Condições

Tipo de estudo

Intervencional

Inscrição (Real)

15

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Oslo, Noruega, 0379
        • Oslo University Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos a 67 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Seven lymphoma survivors will be included, with the same inclusion criteria as in the planned RCT:

Inclusion Criteria:

  • Survivors of Hodgkin and aggressive non-Hodgkin lymphoma, diagnosed 2014 or 2019 (n=7)
  • 18-65 years at diagnosis, and 19-67 years at participation.
  • CF measured by Chalder FQ.
  • Curatively treated, more than 2 years since last treatment.
  • Participation approval from oncologist.

Exclusion Criteria:

  • Indolent non-Hodgkin lymphoma.
  • Fatigue more than one year before the cancer diagnosis.
  • Ongoing cancer treatment, relapse or second cancer, somatic/physical conditions (i.e. severe heart failure/disease, lung disease, use of wheelchair /crutches).
  • Psychiatric disorders (i.e. severe depression, schizophrenia), substance abuse disorder.

In addition, eight cancer survivors with various diagnosis, will be included from a waiting list for rehabilitation at the Cancer Rehabilitation Centre at Aker hospital.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Interdisciplinary complex intervention
The intervention includes patient education, physical exercise, a group-based cognitive behavioral program and individual nutritional counseling

The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.

The patient education will include an online 2-hours group-based patient-education sessions in week 1.

The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.

The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.

The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Recruitment rate
Prazo: The week before the intervention period (week 0)
Assessed by the number who consent to participate
The week before the intervention period (week 0)
Inclusion rate
Prazo: The week before the intervention period (week 0)
Assessed by the number of consenting participants who are included (i.e. have chronic fatigue according to the Fatigue Questionnaire, and are cleared for participation by oncologist after the medical screening).
The week before the intervention period (week 0)
Completion rate
Prazo: The week before the intervention period (week 0)
Assessed by the number of consenting participants consenting patients who complete any measurement at the final assessment
The week before the intervention period (week 0)
Strengths and weaknesses with the inclusion procedure: participants
Prazo: Week 4
Assessed by structured conversations with the participants
Week 4
Strengths and weaknesses with the inclusion procedure: study personnel
Prazo: Week 4
Assessed by structured conversations with the study personnel
Week 4
Feasibility of the patient education session: participants
Prazo: Week 4
Strengths, weaknesses, and usefulness of the contents in the education session will be assessed by structured conversations with the participants after the patient education session.
Week 4
Feasibility of the patient education session: presenters
Prazo: Week 4
Strengths, weaknesses, and usefulness of the contents in the education session will be assessed by structured conversations with the presenters after the patient education session.
Week 4
Feasibility of the exercise program part one (week 1-3): participants
Prazo: Week 4
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the participants
Week 4
Feasibility of the exercise program part one (week 1-3): physiotherapists
Prazo: Week 4
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the physiotherapists
Week 4
Feasibility of the exercise program part two (week 4-7): participants
Prazo: Week 8
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the participants
Week 8
Feasibility of the exercise program part two (week 4-7): physiotherapists
Prazo: Week 8
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the physiotherapists
Week 8
Compliance to the cognitive behavioral therapy groups sessions
Prazo: Week 8
Participation to the cognitive behavioral therapy groups sessions will be registered by the study coordinators/psychologists..
Week 8
Feasibility of the cognitive behavioral therapy groups sessions: participants
Prazo: Week 8
Strengths, weaknesses, and usefulness of the groups sessions will be assessed by structured conversations with the participants after the last group session
Week 8
Feasibility of the cognitive behavioral therapy groups sessions: psychologists
Prazo: Week 8
Strengths, weaknesses, and usefulness of the groups sessions will be assessed by structured conversations with the psychologists after the last group session
Week 8
Compliance to the nutrition counseling
Prazo: Week 11
Participation rate of the individual nutrition counseling sessions will be registered by the clinical dietitian.
Week 11
Feasibility of the nutrition counseling: participants
Prazo: Week 11
Strengths, weaknesses, and usefulness of the contents in the sessions will be assessed by structured conversations with the participants after the last counseling session.
Week 11
Feasibility of the nutrition counseling: clinical dietitian
Prazo: Week 11
Strengths, weaknesses, and usefulness of the contents in the sessions will be assessed by structured conversations with the clinical dietitian after the last counseling session.
Week 11
Compliance to the exercise program: attendance
Prazo: Week 13
Registered by the physiotherapists in an exercise log
Week 13
Compliance to the exercise program: intensity during the aerobic exercise intervals
Prazo: Week 13
Registered by pulse sensors
Week 13
Compliance to the exercise program: implementation of the strength training exercises
Prazo: Week 13
Registered by the physiotherapists in an exercise log
Week 13
Feasibility of the exercise program part three (week 8-12): participants
Prazo: Week 13
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the participants
Week 13
Feasibility of the exercise program part three (week 8-12): physiotherapists
Prazo: Week 13
Strengths and weaknesses with the exercise program will be evaluated through structured conversations with the physiotherapists
Week 13
Feasibility of the questionnaires
Prazo: Week 13
Strengths and weaknesses with the questionnaire will be evaluated through structured conversations with the participants.
Week 13
Feasibility of the physical tests: participants
Prazo: Week 13
Strengths and weaknesses with the tests will be evaluated through structured conversations with the participants.
Week 13
Feasibility of the physical tests: physiotherapists
Prazo: Week 13
Strengths and weaknesses with the tests will be evaluated through structured conversations with the physiotherapists conducting the tests.
Week 13
Compliance to the physical tests
Prazo: Week 13
Assessed by the completion rate of the physical tests (i.e. the number of participants who conduct the tests as planned).
Week 13
Completeness of the questionnaires
Prazo: Week 13
Assessed by the completion rate of the questionnaire (i.e. proportion of missing).
Week 13

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in level of fatigue
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by Chalder Fatigue Questionnaire. Total score range from 0 to 33, with increasing score implying more fatigue.
Change from baseline (week 0) and to post-intervention (week 13)
Change in level of fatigue
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by Chalder Fatigue Questionnaire. Total score range from 0 to 33, with increasing score implying more fatigue.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in level of fatigue
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by Chalder Fatigue Questionnaire. Total score range from 0 to 33, with increasing score implying more fatigue.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in daily functioning and global quality of life
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30). Scores range fro 0 to 100, a higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms.
Change from baseline (week 0) and to post-intervention (week 13)
Change in daily functioning and global quality of life
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30). Scores range fro 0 to 100, a higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in daily functioning and global quality of life
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30). Scores range fro 0 to 100, a higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in subjective well-being
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the Satisfaction with Life Scale. Total score range from 5 to 35, with increasing score implying higher subjective well-being.
Change from baseline (week 0) and to post-intervention (week 13)
Change in vitality
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the Subjective Vitality Scale. The total score ranges from 6 to 36 with a higher score indicating a better condition
Change from baseline (week 0) and to post-intervention (week 13)
Change in general health
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by European Quality of Life Five-dimension Scale Questionnaire (EQ-5D). Total score range from 5 (worst health) to 25 (best health).
Change from baseline (week 0) and to post-intervention (week 13)
Change in work ability
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by Work Ability Index. Total score range from 7 to 49 points, with higher score indicating better work ability.
Change from baseline (week 0) and to post-intervention (week 13)
Change in work ability
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by Work Ability Index. Total score range from 7 to 49 points, with higher score indicating better work ability.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in work ability
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by Work Ability Index. Total score range from 7 to 49 points, with higher score indicating better work ability.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in anxiety symptoms
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the General Anxiety Disorder 7-items. Total score range from 0 to 21 with increasing score implying higher level of anxiety.
Change from baseline (week 0) and to post-intervention (week 13)
Change in anxiety symptoms
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by the General Anxiety Disorder 7-items. Total score range from 0 to 21 with increasing score implying higher level of anxiety.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in anxiety symptoms
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by the General Anxiety Disorder 7-items. Total score range from 0 to 21 with increasing score implying higher level of anxiety.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in depressive symptoms
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the Patient Health Questionnaire-9. Total score from 0 to 27, increasing score implying higher depressive symptoms.
Change from baseline (week 0) and to post-intervention (week 13)
Change in depressive symptoms
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by the Patient Health Questionnaire-9. Total score from 0 to 27, increasing score implying higher depressive symptoms.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in depressive symptoms
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by the Patient Health Questionnaire-9. Total score from 0 to 27, increasing score implying higher depressive symptoms.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in level of physical activity
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the Godin Leisure Time Exercise Questionnaire
Change from baseline (week 0) and to post-intervention (week 13)
Change in level of physical activity
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by the Godin Leisure Time Exercise Questionnaire
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in level of physical activity
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by the Godin Leisure Time Exercise Questionnaire
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in exercise mastery
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Assessed by the Perceived Competence Scale. The scale consists of 4 items (statements). On each item, participants are asked to rate how true a statement is using a 7-point scale.Total score range from 4 to 28, with increasing score reflecting higher exercise mastery.
Change from baseline (week 0) and to post-intervention (week 13)
Change in exercise mastery
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Assessed by the Perceived Competence Scale. The scale consists of 4 items (statements). On each item, participants are asked to rate how true a statement is using a 7-point scale.Total score range from 4 to 28, with increasing score reflecting higher exercise mastery.
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in exercise mastery
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Assessed by the Perceived Competence Scale. The scale consists of 4 items (statements). On each item, participants are asked to rate how true a statement is using a 7-point scale.Total score range from 4 to 28, with increasing score reflecting higher exercise mastery.
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in dietary intake of the participants
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by a digital food frequency questionnaire (DIGIKOST-FFQ)
Change from baseline (week 0) and to post-intervention (week 13)
Change in meal pattern
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by the Meal Pattern Questionnaire
Change from baseline (week 0) and to post-intervention (week 13)
Change in body mass index
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Calculated by measuring weight and height
Change from baseline (week 0) and to post-intervention (week 13)
Change in body mass index
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Calculated by measuring weight and height
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in body mass index
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Calculated by measuring weight and height
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in sleep problems
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Measured by questions from the Trøndelag Health Survey
Change from baseline (week 0) and to post-intervention (week 13)
Change in sleep problems
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Measured by questions from the Trøndelag Health Survey
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in sleep problems
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Measured by questions from the Trøndelag Health Survey
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in cardiorespiratory fitness
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Assessed by a submaximal and indirect treadmill test (modified Balke protocol)
Change from baseline (week 0) and to post-intervention (week 13)
Change in cardiorespiratory fitness
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Assessed by a submaximal and indirect treadmill test (modified Balke protocol)
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in cardiorespiratory fitness
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Assessed by a submaximal and indirect treadmill test (modified Balke protocol)
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in lower body muscle strength
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Assessed by 30 second sit-to-stand test
Change from baseline (week 0) and to post-intervention (week 13)
Change in lower body muscle strength
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Assessed by 30 second sit-to-stand test
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in lower body muscle strength
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Assessed by 30 second sit-to-stand test
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in upper body muscle strength
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Assessed by maximum repetitions of push-ups with various starting positions
Change from baseline (week 0) and to post-intervention (week 13)
Change in upper body muscle strength
Prazo: Change from baseline (week 0) to 4 months follow-up (week 29)
Assessed by maximum repetitions of push-ups with various starting positions
Change from baseline (week 0) to 4 months follow-up (week 29)
Change in upper body muscle strength
Prazo: Change from baseline (week 0) to 7 months follow-up (week 42)
Assessed by maximum repetitions of push-ups with various starting positions
Change from baseline (week 0) to 7 months follow-up (week 42)
Change in quality of life among relatives
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
Assessed by the Research and Development 36-item Short Form Survey (RAND SF-36).The eight scales are standardized with a scoring algorithm or by the SF-36v2 scoring software to obtain a score ranging from 0 to 100. Higher scores indicate better quality of life.
Change from baseline (week 0) and to post-intervention (week 13)
Change in global health status among relatives
Prazo: Change from baseline (week 0) and to post-intervention (week 13)
The global health status / quality of life scale from the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30). Scores range from 0 to 100, a higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms.
Change from baseline (week 0) and to post-intervention (week 13)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de abril de 2021

Conclusão Primária (Real)

31 de janeiro de 2022

Conclusão do estudo (Real)

31 de janeiro de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

16 de abril de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de junho de 2021

Primeira postagem (Real)

18 de junho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de abril de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de abril de 2022

Última verificação

1 de abril de 2022

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 153665

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever